Biocracked
**Approach:** Lab in action. **Palette:** Bold color field, mustard yellow.

A close, slightly high three-quarter view of a hand in a magenta-purple nitrile glove holding a clear 12-well cell culture plate. Each well is filled with salmon-pink culture medium. A multichannel pipette hovers over one well, with a single droplet caught just before it falls. The background is a seamless, saturated mustard-yellow surface and wall, with a soft shadow under the plate. Bright, even studio light comes from the upper left, giving crisp highlights on the plastic rims and a soft glow through the liquid. The depth of field is shallow, so the far wells blur gently. A tiny electric-green cap on a tube sits in the corner of the frame. The mood is calm, precise and curious, with a clean, graphic, editorial feel. No text or labels.
Peptides

Semaglutide Didn't Shrink Human Muscle Cells. So Why the Muscle Loss?

Dr. Synapse · · 5 min read

Weight-loss headlines about semaglutide and its cousins keep circling one worry: that the drugs eat muscle. A new study in GeroScience suggests that, at least at the level of the muscle cell itself, the accusation may be misplaced. When researchers applied semaglutide or GIP directly to primary human myotubes, the cells did not waste. They did not switch on atrophy genes, release a worrying cocktail of inflammatory proteins, or lose thickness.

The finding does not make the lean mass problem disappear. It relocates it.

The Question Behind the Study

In clinical trials, GLP-1 receptor agonists and dual GIP/GLP-1 agonists produce striking weight loss. They also produce a measurable loss of lean body mass, which includes skeletal muscle, as part of that weight change. For older adults, who already face a gradual decline in muscle (sarcopenia), that matters a great deal.

There are two broad explanations. The first is a direct pharmacological effect, meaning the drug acts on muscle tissue and pushes it toward breakdown. The second is indirect: people eat much less, often get less protein, and move or load their bodies less, so muscle shrinks the way it would with any large energy deficit. Ditchfield, Macleod and Price set out to test the first possibility in a clean experimental system.

How the Experiment Worked

The team isolated primary myoblasts, the precursor cells of muscle fibers, from skeletal muscle of older adults with obesity who were undergoing orthopaedic surgery. That donor population is deliberately relevant: it resembles the people most likely to be prescribed incretin therapy and most vulnerable to muscle loss.

The researchers first asked whether these cells carry the right receptors. They then differentiated the cells into myotubes and treated them with semaglutide or GIP peptide. Readouts included:

  • Atrophy-related gene expression by qPCR
  • Secretome changes using the Olink Reveal proteomic panel
  • Mitochondrial and glycolytic energy metabolism using Seahorse XF ATP rate assays, glucose uptake and lactate secretion
  • Myotube thickness and differentiation using immunofluorescence

Receptors: GIPR Present, GLP-1R Barely There

GIPR mRNA was consistently detected in cells from every donor. GLP-1R told a different story. Its mRNA was undetectable by PCR. Using LUXendin645 flow cytometry in a subset of three donors, however, the team found low-level GLP-1R protein at the cell surface in roughly 51 to 66 percent of myoblasts.

That result is a useful reminder that receptor detection depends on the method. Absent mRNA does not always mean absent protein, and a low density of surface receptors may still matter, though here it did not translate into major cellular effects. The authors' data suggest that human muscle cells are, at best, modestly equipped to respond to GLP-1 directly.

No Atrophy Signal, No Secretome Alarm

The headline result is what did not happen. Neither semaglutide nor GIP altered the expression of atrophy-related genes. The secretome analysis, which looks at proteins released by the cells, found nothing reaching statistical significance. If the drugs were poisoning muscle, or pushing it to send distress signals, this is where it would likely appear.

Myotube thickness and differentiation were also preserved. Neither treatment impaired the ability of cells to fuse and form myotubes, so myogenesis appeared intact.

A Small Metabolic Wrinkle

There was one measurable effect. Semaglutide reduced glycolytic and total ATP production rates, with reduced lactate secretion, pointing to a modest suppression of glycolytic flux. Mitochondrial parameters were unaffected.

This is a subtle shift rather than a sign of cellular damage, and the study does not show it harms muscle function. Still, it is a signal worth following. Whether a small reduction in glycolytic output matters in living muscle, where fuel supply, hormones and nerve activity all interact, remains an open question.

GIP Might Even Help

In a twist, GIP increased myotube thickness after eight days of treatment. This was an in vitro observation and should not be read as evidence that GIP builds muscle in people. But it does cut against the notion that incretin signaling is inherently catabolic for muscle cells. It also adds some nuance to dual agonists such as tirzepatide, which engage both GIP and GLP-1 pathways.

What This Means for Older Adults

The authors conclude that direct activation of GLP-1 and GIP receptors did not produce major atrophic, inflammatory, morphological, myogenic or mitochondrial effects in these cells. That is consistent with an indirect mechanism for the lean mass loss seen clinically.

If that interpretation holds, the practical focus shifts from the drug as a muscle toxin to the context in which it is used:

  • Energy deficit: large, rapid weight loss tends to cost lean tissue regardless of how it is achieved.
  • Protein intake: appetite suppression can leave older adults under-eating protein.
  • Mechanical loading: less activity and lower body mass reduce the stimulus muscles receive. Resistance training is the obvious countermeasure.

These are not new ideas, but this study adds cell-level support for prioritizing them. It suggests that protecting muscle during incretin therapy may depend more on diet quality and exercise than on avoiding a specific drug.

Important Caveats

This is an in vitro study. Myotubes grown in a dish lack blood flow, nerves, circulating hormones, immune cells and the whole-body energy deficit that accompanies treatment. Drugs could affect muscle indirectly through other organs, such as through appetite centers, adipose tissue, gut hormones or inflammation, none of which this model captures. The GLP-1R protein analysis was limited to three donors, and donors were older adults with obesity undergoing orthopaedic surgery, which may not represent all patients. Exposure conditions in a dish also may not mirror drug levels in muscle tissue.

The results show that direct receptor-mediated muscle wasting is not obvious in this model. They do not prove that these drugs are muscle-neutral in people.

The Bottom Line

For anyone worried that semaglutide is quietly dissolving muscle cell by cell, this study offers some reassurance: human myotubes exposed to semaglutide or GIP did not show the molecular or structural hallmarks of atrophy. The bigger risk is likely the circumstances around the drug, namely eating far less, getting less protein and moving less. Clinical trials that combine incretin therapy with protein targets and resistance exercise in older adults will be the real test of that idea.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Macro science, the human outcome angle through tissue. Palette: D, bold color field.

Extreme close-up of a cross-section of raw beef thigh muscle, used as a stand-in for human thigh tissue. It is shot straight on and slightly from above, on a saturated tomato-red seamless backdrop. Fine white fat marbling threads run through the dark red muscle fibers. On one half the marbling is dense and lacy, and on the other it is sparse and clean, so the contrast reads as a before and after. A thin, translucent calipers-style steel ruler lies along the edge, with no markings readable. Lighting is soft, directional studio light from the upper left, with crisp highlights on the glistening fibers and gentle warm shadows. A single small electric green surgical marker dot sits on the tissue. The mood is analytical, tense and uncertain, with shallow depth of field and sharp detail on the fat texture.
longevity

High-Dose Semaglutide and Thigh Muscle: What the MRI Shows

BY HELIX WARD ·

A new MRI sub-analysis of the STEP UP trial examined what 72 weeks of high-dose semaglutide (7.2 mg) does to body composition, including the thigh muscles. Fat loss was large, about 11 liters versus placebo, and fat infiltration within thigh muscle fell significantly. Thigh muscle volume dropped by about 1.1 L, a change that missed statistical significance (p = 0.07) but whose confidence interval leans toward loss. With only 55 scanned participants, just six on placebo, and Novo Nordisk involvement, the findings are suggestive rather than conclusive. Here's what the data show, what they can't, and how to protect your muscle on a GLP-1.

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

On Tirzepatide? Lifting Weights Saved 1.1 kg of Lean Mass

BY REX MERIDIAN ·

Tirzepatide can melt away over 22 kg in 40 weeks, but it also takes lean tissue and strength with it. A new randomized trial of 120 adults tested whether lifting weights three times a week could change that. Fat loss stayed the same, but lifters lost about 1.1 kg less lean soft tissue. Strength fell in the drug-only group and rose in every test among lifters. Here are the numbers and what they mean for anyone on Mounjaro or Zepbound.

Approach: 3, the human outcome, here as an animal-science moment. Palette: C, natural.

An old female lab mouse with slightly greying, ruffled fur sits upright on a researcher's open gloved palm, photographed at eye level in a close side-on view with a shallow depth of field. Behind it, a softly blurred animal facility window pours in real morning daylight, giving the scene a pale green-grey and warm-wood setting. The nitrile glove is a vivid electric green (#00e676), the single saturated accent. The mouse's whiskers and pink ears catch the light, and the researcher's white coat sleeve is just visible. Tones are natural: skin, soft cream bedding, sage walls. The mood is calm, careful and quietly hopeful, and it conveys age and care rather than drama. The image has no text, no labels and no readable writing.
longevity

Ozempic's Active Ingredient Extended Lifespan in Old Mice. Here's Why

BY DR. SYNAPSE ·

Semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan in old female mice in a new Nature study from UC Berkeley. Treatment began at 20 months of age and mimicked many benefits of calorie restriction. In a direct comparison, the drug also showed more favourable trajectories than matched calorie restriction in exploratory drive, spatial memory and glucose control. But this is mouse research in females only, with no dosing guidance for humans. Here is what the findings suggest, and what they do not.

**Approach: Conceptual metaphor. Palette: D, bold color field.**

A single clear glass of water sits on a saturated mustard-yellow backdrop, shot at a slight low three-quarter angle. A hand-held pen injector rests beside it, its body a matte white with a small electric green dial ring as the only green accent. Hard but clean studio light from the upper left throws a crisp, defined shadow across the yellow surface. Through the glass, the injector is refracted into two slightly offset images, suggesting a signal that is split and hard to read. The mood is calm, questioning and balanced, with no drama. The background is fully warm and bright, with no blue cast. The surface has a subtle paper-like texture. There is no text, no label and no face.
metabolism

Do Ozempic and Mounjaro Cause Depression? What 20 Studies Found

BY DR. SYNAPSE ·

Do Ozempic and Mounjaro cause depression or suicidal thoughts? A new systematic review of 20 studies plus EMA and FDA assessments says the best evidence doesn't show it. Randomized data, including two large 2025 meta-analyses, found no increased suicidality, depression, or anxiety with semaglutide or tirzepatide. The scarier signals came from study designs that can't separate drug effects from obesity-related distress, baseline psychiatric risk, and reporting bias. But trials excluded many psychiatric patients, so surveillance still matters for high-risk groups and rare long-term outcomes.

This page is available in